



Lancaster 2405 Columbus Street Suite# 210 Lancaster, Ohio 43130

Alglucosidase alfa (Lumizyme) Provider Order Form

Date: _____

PATIENT	INFORMATION
Name:	DOB: SEX: M 🗆 F 🗆
ICD-10 code (required):	ICD-10 description:
□NKDA Allergies:	Weight lbs/kg:
REFERRAL STATUS	
□New Referral □Referral Renewal □Medication/Order Change □Benefits Verification Only □Discontinuation Order	
PHYSICIAN INFORMATION	
Referral Coordinator Name:	Referral Coordinator Email:
Ordering Provider:	Provider NPI:
Referring Practice Name:	Phone: Fax:
Practice Address:	City: State: Zip Code:
LABORATORY ORDERS	THERAPY ADMINISTRATION
□ CBC □ at each dose □ every	Alglucosidase alfa (Lumizyme) in 0.9% sodium chloride,
□ CMP □ at each dose □ every	intravenous infusion, final concentration of 0.5 to 4mg/ml,
\Box CRP \Box at each dose \Box every	administer with 0.2 micron filter
□ Other:	 Dose:
	■ Frequency: □ every 2 weeks □ other
PRE-MEDICATION ORDERS	 Administer over approximately 4 hours, in a step wise
□ acetaminophen (Tylenol) □ 500mg / □ 650mg / □ 1000mg PO	manner. Initial infusion rate should be no more than
□ cetirizine (Zyrtec) 10mg PO	1mg/k g/hr. Infusion rate may be increased by 2mg/kg/hr
□ loratadine (Claritin) 10mg PO	every 30 minutes after patient tolerance is established.
□ diphenhydramine (Benadryl) □ 25 mg / □ 50 mg □ PO / □ IV	Max rate is 7mg/kg/hr. If the patient is stable,
□ methylprednisolone (Solu-Medrol)□ 40mg / □ 125mg IV	alglucosidase alfa may be administered at the maximum
	rate of 7mg/kg/hr until the infusion is completed
Other: Dose: Route:	\square Flush with 0.9% sodium chloride at the completion of infusion
Frequency: Koule	
nequency	Patient is required to stay for 30-minute observation period
SPECIAL INSTRUCTIONS	□ Patient is NOT required to stay for observation time
	□ Refills: □ Zero / □ for 12 months / □
	(if not indicated order will expire one year from date signed)
	Total dosages
	Refills
NOTES/ADDITIONAL COMMENTS:	
ORDERING PROVIDER	
	Data
Signature <u>X</u>	Date
Provider	Phone Fax